NASDAQ:MXCT MaxCyte (MXCT) Stock Price, News & Analysis $1.38 -0.05 (-3.50%) Closing price 04:00 PM EasternExtended Trading$1.39 +0.01 (+1.01%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About MaxCyte Stock (NASDAQ:MXCT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MaxCyte alerts:Sign Up Key Stats Today's Range$1.36▼$1.5050-Day Range$1.38▼$2.3952-Week Range$1.36▼$5.20Volume1.40 million shsAverage Volume587,734 shsMarket Capitalization$147.12 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingModerate Buy Company Overview MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland. Read More MaxCyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreMXCT MarketRank™: MaxCyte scored higher than 48% of companies evaluated by MarketBeat, and ranked 573rd out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingMaxCyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMaxCyte has only been the subject of 2 research reports in the past 90 days.Read more about MaxCyte's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for MaxCyte are expected to grow in the coming year, from ($0.42) to ($0.41) per share.Price to Book Value per Share RatioMaxCyte has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.56% of the float of MaxCyte has been sold short.Short Interest Ratio / Days to CoverMaxCyte has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in MaxCyte has recently increased by 1.16%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMaxCyte does not currently pay a dividend.Dividend GrowthMaxCyte does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.56% of the float of MaxCyte has been sold short.Short Interest Ratio / Days to CoverMaxCyte has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in MaxCyte has recently increased by 1.16%, indicating that investor sentiment is decreasing. News and Social Media1.6 / 5News Sentiment-0.03 News SentimentMaxCyte has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for MaxCyte this week, compared to 2 articles on an average week.Search Interest2 people have searched for MXCT on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MaxCyte insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.30% of the stock of MaxCyte is held by insiders.Percentage Held by Institutions68.81% of the stock of MaxCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MaxCyte's insider trading history. Receive MXCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address MXCT Stock News HeadlinesMaxCyte, Inc. (MXCT) Q2 2025 Earnings Call TranscriptAugust 7 at 4:00 AM | seekingalpha.comMaxCyte (MXCT) Q2 Revenue Drops 18%August 6 at 12:01 AM | fool.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.August 8 at 2:00 AM | Brownstone Research (Ad)MaxCyte Inc (MXCT) Q2 2025 Earnings Report Preview: What To ExpectAugust 6 at 10:50 PM | finance.yahoo.comMaxCyte (MXCT) Projected to Post Earnings on WednesdayAugust 5 at 3:04 AM | americanbankingnews.comMaxCyte Signs Platform License Agreement with Adicet BioAugust 4, 2025 | globenewswire.comMaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy PipelineJuly 31, 2025 | globenewswire.comMaxCyte to Report Second Quarter 2025 Financial Results ... - MorningstarJuly 11, 2025 | morningstar.comMSee More Headlines MXCT Stock Analysis - Frequently Asked Questions How have MXCT shares performed this year? MaxCyte's stock was trading at $4.16 at the beginning of the year. Since then, MXCT shares have decreased by 66.8% and is now trading at $1.38. How were MaxCyte's earnings last quarter? MaxCyte, Inc. (NASDAQ:MXCT) announced its quarterly earnings data on Wednesday, August, 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.02. The business had revenue of $8.51 million for the quarter, compared to the consensus estimate of $9.57 million. MaxCyte had a negative net margin of 125.22% and a negative trailing twelve-month return on equity of 22.12%. Read the conference call transcript. When did MaxCyte IPO? MaxCyte (MXCT) raised $150 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 12,000,000 shares at a price of $11.50-$13.50 per share. Who are MaxCyte's major shareholders? Top institutional shareholders of MaxCyte include Geode Capital Management LLC (2.33%), Chevy Chase Trust Holdings LLC (1.62%), Rathbones Group PLC (0.22%) and Los Angeles Capital Management LLC (0.06%). Insiders that own company stock include Casdin Partners Master Fund, L, Douglas Doerfler, Stanley C Erck, John Joseph Johnston, Douglas J Swirsky, Richard Douglas, Maher Masoud, David I Sandoval, Ali Soleymannezhad and Thomas M Ross. View institutional ownership trends. How do I buy shares of MaxCyte? Shares of MXCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MaxCyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that MaxCyte investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings8/06/2025Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBusiness Services Current SymbolNASDAQ:MXCT CIK1287098 Webmaxcyte.com Phone301-944-1700Fax301-944-1703Employees80Year FoundedN/APrice Target and Rating Average Price Target for MaxCyte$7.00 High Price Target$9.00 Low Price Target$6.00 Potential Upside/Downside+407.2%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$41.06 million Net Margins-125.22% Pretax Margin-110.92% Return on Equity-21.70% Return on Assets-18.71% Debt Debt-to-Equity RatioN/A Current Ratio12.23 Quick Ratio11.58 Sales & Book Value Annual Sales$37.68 million Price / Sales3.90 Cash FlowN/A Price / Cash FlowN/A Book Value$1.95 per share Price / Book0.71Miscellaneous Outstanding Shares106,416,000Free Float102,904,000Market Cap$146.85 million OptionableOptionable Beta1.23 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:MXCT) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredChina's 500 Million Year AdvantageThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MaxCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.